Identification of transcriptomic determinants to predict the efficacy of anti-EGFR treatment of colorectal cancer patients.

被引：0
|
作者：
Chowdhury, Saikat [1 ]
Shen, John Paul Y. C. [1 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 03期
关键词：
D O I：
10.1200/JCO.2021.39.3_suppl.130
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
130
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Novel approaches to treatment of advanced colorectal cancer with anti-EGFR monoclonal antibodies
    Zhang, Wu
    Gordon, Michael
    Lenz, Heinz-Josef
    ANNALS OF MEDICINE, 2006, 38 (08) : 545 - 551
  • [32] Optimizing treatment of metastatic colorectal cancer patients with anti-EGFR antibodies: overcoming the mechanisms of cancer cell resistance
    Troiani, Teresa
    Zappavigna, Silvia
    Martinelli, Erika
    Addeo, Santolo R.
    Stiuso, Paola
    Ciardiello, Fortunato
    Caraglia, Michele
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2013, 13 (02) : 241 - 255
  • [33] Place of anti-EGFR therapy in older patients with metastatic colorectal cancer in 2020
    Gilabert, Marine
    Ries, Pauline
    Chanez, Brice
    Triby, Simon
    Francois, Eric
    Lievre, Astrid
    Rousseau, Frederique
    JOURNAL OF GERIATRIC ONCOLOGY, 2020, 11 (08) : 1229 - 1236
  • [34] A synonymous EGFR polymorphism predicting responsiveness to anti-EGFR therapy in metastatic colorectal cancer patients
    Bonin, Serena
    Donada, Marisa
    Bussolati, Gianni
    Nardon, Ermanno
    Annaratone, Laura
    Pichler, Martin
    Chiaravalli, Anna Maria
    Capella, Carlo
    Hoefler, Gerald
    Stanta, Giorgio
    TUMOR BIOLOGY, 2016, 37 (06) : 7295 - 7303
  • [35] Doxycycline as preventive treatment of skin toxicity in patients with metastatic colorectal cancer treated with an anti-EGFR and chemotherapy
    Ramirez Daffos, P.
    Jimenez, E.
    Bolanos Naranjo, M.
    Gonzalez-Astorga, B.
    Rubiales, S.
    Ceballos Barbancho, E.
    Rodriguez, J.
    Reina Zoilo, J.
    ANNALS OF ONCOLOGY, 2021, 32 : S117 - S117
  • [36] Safety and efficacy of modified schedula of anti-EGFR monoclonal antibodies plus chemotherapy as first line treatment in metastatic colorectal cancer patients
    Mancarella, S.
    Poti, O.
    De Giorgi, D.
    Schirinzi, M. L.
    De Maria, G.
    Rizzo, A.
    De Benedittis, A.
    Galante, M. M.
    ANNALS OF ONCOLOGY, 2015, 26 : 52 - 52
  • [37] IMMUNOLOGICAL EFFECTS OF DIFFERENT ANTI-EGFR ANTIBODIES IN METASTATIC COLORECTAL CANCER PATIENTS
    Manzoni, M.
    Delfanti, S.
    Rovati, B.
    Brugnatelli, S.
    Ronzoni, M.
    Perfetti, V
    Mariucci, S.
    Loupakis, F.
    Danova, M.
    ANNALS OF ONCOLOGY, 2010, 21 : 33 - 33
  • [38] Molecular predictive factors of response to anti-EGFR antibodies in colorectal cancer patients
    Santini, Daniele
    Pantano, Francesco
    Vincenzi, Bruno
    Loupakis, Fotios
    Caraglia, Michele
    Falcone, Alfredo
    Tonini, Giuseppe
    EJC SUPPLEMENTS, 2008, 6 (14): : 86 - 90
  • [39] Tumor bulk to predict clinical outcomes of anti-EGFR therapy in treatment refractory metastatic colorectal cancer independent of sidedness
    Kratz, Jeremy D.
    LoConte, Noelle K.
    Lubner, Sam Joseph
    Mulkerin, Daniel
    Uboha, Nataliya Volodymyrivna
    Deming, Dustin A.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [40] Association of bevacizumab-free interval with efficacy of anti-EGFR therapy in patients with metastatic colorectal cancer.
    Komori, Azusa
    Taniguchi, Hiroya
    Narita, Yukiya
    Uegaki, Shiori
    Nitta, Sohhei
    Yamaguchi, Kazuhisa
    Nomura, Motoo
    Kadowaki, Shigenori
    Takahari, Daisuke
    Ura, Takashi
    Andoh, Masashi
    Muro, Kei
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (03)
12345